A Rapid, Semi-Quantitative Assay to Screen for Modulators of Alpha-Synuclein Oligomerization Ex vivo

Frontiers in Neuroscience
Marion DelenclosPamela J McLean

Abstract

Alpha synuclein (αsyn) aggregates are associated with the pathogenesis of Parkinson's disease and others related disorders. Although modulation of αsyn aggregation is an attractive therapeutic target, new powerful methodologies are desperately needed to facilitate in vivo screening of novel therapeutics. Here, we describe an in vivo rodent model with the unique ability to rapidly track αsyn-αsyn interactions and thus oligomerization using a bioluminescent protein complementation strategy that monitors spatial and temporal αsyn oligomerization ex vivo. We find that αsyn forms oligomers in vivo as early as 1 week after stereotactic AAV injection into rat substantia nigra. Strikingly, although abundant αsyn expression is also detected in striatum at 1 week, no αsyn oligomers are detected at this time point. By 4 weeks, oligomerization of αsyn is detected in both striatum and substantia nigra homogenates. Moreover, in a proof-of-principle experiment, the effect of a previously described Hsp90 inhibitor known to prevent αsyn oligomer formation, demonstrates the utility of this rapid and sensitive animal model to monitor αsyn oligomerization status in the rat brain.

References

Mar 1, 1996·Journal of Neuropathology and Experimental Neurology·L S Forno
Aug 28, 1997·Nature·M G SpillantiniM Goedert
Dec 19, 1998·Molecular Psychiatry·M Goedert, M G Spillantini
Mar 27, 1999·The Journal of Biological Chemistry·L NarhiM Citron
Oct 12, 1999·Brain Pathology·D W DicksonS H Yen
Mar 27, 2004·The Journal of Biological Chemistry·Jochen KluckenPamela J McLean
Jul 24, 2004·Nature Medicine·Christopher A Ross, Michelle A Poirier
Sep 11, 2004·Biochemical and Biophysical Research Communications·Pamela J McLeanBradley T Hyman
Sep 29, 2004·Lancet·Marie-Christine Chartier-HarlinAlain Destée
Feb 25, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Bakhos A TannousXandra O Breakefield
Mar 2, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Omar M A El-AgnafDavid Allsop
Nov 14, 2006·Nature Methods·Ingrid Remy, Stephen W Michnick
Jan 15, 2009·The Journal of Biological Chemistry·Sharareh EmadiMichael R Sierks
Nov 26, 2009·The Journal of Pharmacology and Experimental Therapeutics·Preeti PutchaPamela J McLean
May 21, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Evangelia EmmanouilidouKostas Vekrellis
Jun 8, 2010·Molecular Neurodegeneration·Wenjie LuoGabriela Chiosis
Sep 30, 2010·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Karin M DanzerPamela J McLean
Oct 15, 2010·CNS & Neurological Disorders Drug Targets·S K KaliaP J McLean
Feb 18, 2011·Proceedings of the National Academy of Sciences of the United States of America·Beate WinnerRoland Riek
Jul 2, 2011·Acta Neuropathologica·Glenda M HallidayDennis W Dickson
Oct 19, 2011·Proceedings of the National Academy of Sciences of the United States of America·Wei WangQuyen Q Hoang
Mar 23, 2012·Chembiochem : a European Journal of Chemical Biology·Malte DrescherVinod Subramaniam
Aug 28, 2012·Molecular Neurodegeneration·Karin M DanzerPamela J McLean
Dec 12, 2012·Annals of Neurology·Lorraine V KaliaAnthony E Lang
Feb 13, 2013·Journal of the American Chemical Society·Thomas GurryCollin M Stultz
Jun 15, 2013·Nature·Jacqueline BurréThomas C Südhof
Nov 7, 2013·Neuro-degenerative Diseases·Dennis SelkoeTim Bartels
Nov 21, 2013·Acta Neuropathologica Communications·Hemi DimantPamela J McLean
Jan 11, 2014·Therapeutic Advances in Neurological Disorders·Daryl Rhys JonesPamela McLean
Dec 5, 2014·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Sarah-Ann AelvoetVeerle Baekelandt
Jan 13, 2015·Alzheimer's Research & Therapy·Woojin Scott KimGlenda M Halliday
Feb 14, 2015·Biological Psychiatry·Urmi SenguptaRakez Kayed
Mar 19, 2015·Expert Opinion on Therapeutic Targets·Simon MoussaudPamela J McLean
Jul 15, 2015·Proceedings of the National Academy of Sciences of the United States of America·Ulf DettmerDennis Selkoe

❮ Previous
Next ❯

Citations

Jan 15, 2020·Molecular Neurodegeneration·Jae-Hyeon ParkPamela J McLean

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
PCR
ELISA
PCA
transgenic

Software Mentioned

ImageJ
Stereo Investigator
GraphPad Prism

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Alpha-Synuclein Aggregation

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

© 2021 Meta ULC. All rights reserved